Zag Bio is a biotechnology company developing thymus‑targeted therapies to induce T‑cell central tolerance and treat autoimmune diseases. Their platform uses bifunctional antibodies that deliver self‑antigens to antigen‑presenting cells in the thymus, training immune cells to recognize and protect the body’s own tissues, with pipelines that include programs such as ZAG‑101 for type 1 diabetes.
No recent news for this company.